.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,221,392

« Back to Dashboard
Patent 6,221,392 protects FLUXID, NIRAVAM, KEMSTRO, FAZACLO ODT, and REGLAN ODT, and is included in five NDAs. There has been one Paragraph IV challenge on Niravam. There are four tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirteen patent family members in nine countries.

Summary for Patent: 6,221,392

Title: Rapidly dissolving robust dosage form
Abstract:The invention is directed to a hard tablet that can be stored, packaged and processed in bulk. Yet the tablet dissolves rapidly in the mouth of the patient with a minimum of grit. The tablet is created from an active ingredient mixed into a matrix of a nondirect compression filler and a relatively high lubricant content.
Inventor(s): Khankari; Rajendra K. (Maple Grove, MN), Hontz; John (Plymouth, MN), Chastain; Sara J. (Maple Grove, MN), Katzner; Leo (Eden Prairie, MN)
Assignee: Cima Labs Inc. (Eden Prairie, MN)
Application Number:09/464,882
Patent Claim Types:
see list of patent claims
Composition; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 14th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ucb Inc
FLUXID
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL021712-001Sep 24, 2004DISCNNo6,221,392► subscribeY
Ucb Inc
FLUXID
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL021712-002Sep 24, 2004DISCNNo6,221,392► subscribeY
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-001Jan 19, 2005DISCNNo6,221,392► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,221,392

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,024,981 Rapidly dissolving robust dosage form► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,221,392

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia6896998► subscribe
Australia726336► subscribe
Canada2284663► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc